What is Laboratorios Farmaceuticos Rovi Days Payable?
Laboratorios Farmaceuticos RoviXMAD:ROVI -0.17%93 Days Payable is 120.63 as of Mar. 2026, which is 6% below its 10-year median of 127.75. GuruFocus rates XMAD:ROVI with a GF Score™ of 93/100 and a GF Value™ of €50.99 (Modestly Overvalued). The stock has 1 warning sign investors should review. Among 922 Drug Manufacturers companies, Laboratorios Farmaceuticos Rovi ranks better than 65.08% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Laboratorios Farmaceuticos Rovi Days Payable Chart
XMAD:ROVI vs ZTS, UTHR, VTRS: Days Payable Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Laboratorios Farmaceuticos Rovi's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Laboratorios Farmaceuticos Rovi Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Laboratorios Farmaceuticos Rovi's Days Payable distribution charts can be found below:
* The bar in red indicates where Laboratorios Farmaceuticos Rovi's Days Payable falls into.
Laboratorios Farmaceuticos Rovi Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Laboratorios Farmaceuticos Rovi (XMAD:ROVI) has a Days Payable of 120.63 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Laboratorios Farmaceuticos Rovi and its competitors. This is near median its historical median of 127.75. Over the past decade, Laboratorios Farmaceuticos Rovi's Days Payable has ranged from 111.26 to 155.86. According to the industry distribution chart, Laboratorios Farmaceuticos Rovi ranks #322 out of 922 companies in the Drug Manufacturers industry, placing it in the top 34.9%.
Is Laboratorios Farmaceuticos Rovi's Days Payable too high?
Laboratorios Farmaceuticos Rovi's current Days Payable of 120.63 is near median its 10-year median of 127.75. Over the past 10 years, this metric has ranged from a low of 111.26 to a high of 155.86. The Drug Manufacturers industry median Days Payable is 90.84. Laboratorios Farmaceuticos Rovi's value of 120.63 is 32.8% above this industry median. Based on the distribution chart, Laboratorios Farmaceuticos Rovi ranks #322 out of 922 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Laboratorios Farmaceuticos Rovi has a GF Score™ of 93/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Laboratorios Farmaceuticos Rovi's Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Laboratorios Farmaceuticos Rovi ranks #322 out of 922 companies for Days Payable. This puts Laboratorios Farmaceuticos Rovi in the upper half of its industry. The industry median Days Payable is 90.84. Laboratorios Farmaceuticos Rovi's value of 120.63 is 32.8% above this benchmark. Historically, Laboratorios Farmaceuticos Rovi's own Days Payable has ranged from 111.26 to 155.86 over the past decade. While the company's 10-year median is 127.75 vs. the industry median of 90.84, Laboratorios Farmaceuticos Rovi has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.84, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Laboratorios Farmaceuticos Rovi's current Days Payable of 120.63 is 32.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Laboratorios Farmaceuticos Rovi and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Laboratorios Farmaceuticos Rovi's current Days Payable is 120.63, which is near median its own 10-year median of 127.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Laboratorios Farmaceuticos Rovi stock overvalued right now?
Based on GuruFocus' analysis, Laboratorios Farmaceuticos Rovi (XMAD:ROVI) is currently considered Modestly Overvalued. The stock's GF Value™ is €50.99, compared to a current price of €57.40 — trading 12.6% above its estimated fair value. The current Days Payable is 120.63, which is near median its 10-year median of 127.75 and 32.8% above the Drug Manufacturers industry median of 90.84. Laboratorios Farmaceuticos Rovi's overall GF Score™ is 93/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Laboratorios Farmaceuticos Rovi (XMAD:ROVI), the current Days Payable is 120.63 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Laboratorios Farmaceuticos Rovi (XMAD:ROVI) Overvalued in 2026?
Based on GuruFocus' analysis, Laboratorios Farmaceuticos Rovi stock appears to be overvalued.
The current stock price of €57.40 is trading 12.6% above its estimated GF Value™ of €50.99.
GuruFocus considers Laboratorios Farmaceuticos Rovi to be Modestly Overvalued.
Key valuation signals for XMAD:ROVI:
Days Payable: 120.63 (near median its 10-year median of 127.75)
GF Value™: €50.99 vs. price of €57.40 (12.6% above fair value)
Industry Position: 32.8% above the Drug Manufacturers median (#322 of 922)
No single metric tells the full story. See the XMAD:ROVI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Laboratorios Farmaceuticos Rovi Business Description
Laboratorios Farmaceuticos Rovi SA is a biotechnology company engaged in the research, development, manufacturing, and marketing of small molecule and specialty biologic drugs. The company has a diversified portfolio of products that it markets in Spain through its specialized sales force of specialist physicians, hospitals and pharmacies. Laboratorios' research and development pipeline is focused on the expansion of applications, indications, and alternative mechanisms of action for heparin-derived products. The company aims to obtain new pharmaceutical products that enable the regular administration of formulations that are administered daily in chronic and prolonged treatments. Its two segments are Manufacturing and Marketing.
93GF Score
Get the complete analysis for XMAD:ROVI
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAD:ROVI has been successfully added to your 
